Revolution Medicines Looks to Raise $158M in Proposed Public Offering

NEW YORK – Precision oncology-focused Revolution Medicines announced on Monday after the close of the market that it is hoping to raise approximately $158 million in net proceeds from an underwritten public offering of 4,000,000 shares of its common stock at $42.14 per share, the last reported stock price on the Nasdaq on Jan. 29.